Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09NMD
|
||||
Former ID |
DAP001445
|
||||
Drug Name |
Lasofoxifene
|
||||
Synonyms |
Oporia; Lasofoxifene [INN]; CP 336156; CP-336,156; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Approved | [1], [2] | ||
Company |
Pfizer
|
||||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C28H31NO2
|
||||
InChI |
InChI=1S/C28H31NO2/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2/t26-,28+/m1/s1
|
||||
InChIKey |
GXESHMAMLJKROZ-IAPPQJPRSA-N
|
||||
CAS Number |
CAS 180916-16-9
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9372902, 14831231, 14904412, 24770716, 30420129, 49688680, 50075362, 50359465, 53787068, 57399782, 103314903, 113461635, 126667068, 128019372, 134338645, 134339082, 135136354, 135341628, 136946558, 137115371, 142314011, 144116131, 163125974, 164228137, 164834342, 179150118, 187051843, 198945374, 204370304, 223662242, 223741437, 226414580
|
||||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Modulator | [2] | |
KEGG Pathway | Estrogen signaling pathway | ||||
Prolactin signaling pathway | |||||
Thyroid hormone signaling pathway | |||||
Endocrine and other factor-regulated calcium reabsorption | |||||
Proteoglycans in cancer | |||||
NetPath Pathway | FSH Signaling Pathway | ||||
EGFR1 Signaling Pathway | |||||
RANKL Signaling Pathway | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
Reactome | Nuclear signaling by ERBB4 | ||||
Nuclear Receptor transcription pathway | |||||
WikiPathways | Estrogen signaling pathway | ||||
Nuclear Receptors Meta-Pathway | |||||
Estrogen Receptor Pathway | |||||
Signaling by ERBB4 | |||||
JAK/STAT | |||||
Integrated Pancreatic Cancer Pathway | |||||
Leptin signaling pathway | |||||
miR-targeted genes in muscle cell - TarBase | |||||
Integrated Breast Cancer Pathway | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7542). | ||||
REF 2 | Pfizer. Product Development Pipeline. March 31 2009. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.